DE602004017477D1 - Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential - Google Patents

Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential

Info

Publication number
DE602004017477D1
DE602004017477D1 DE602004017477T DE602004017477T DE602004017477D1 DE 602004017477 D1 DE602004017477 D1 DE 602004017477D1 DE 602004017477 T DE602004017477 T DE 602004017477T DE 602004017477 T DE602004017477 T DE 602004017477T DE 602004017477 D1 DE602004017477 D1 DE 602004017477D1
Authority
DE
Germany
Prior art keywords
oil
water emulsion
cationic agent
low concentration
zeta potential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004017477T
Other languages
English (en)
Inventor
Severine Bague
Betty Philips
Jean-Sebastien Garrigue
Laura Rabinovich-Guilatt
Gregory Lambert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novagali SA
Original Assignee
Novagali SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004017477(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novagali SA filed Critical Novagali SA
Publication of DE602004017477D1 publication Critical patent/DE602004017477D1/de
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)
DE602004017477T 2004-11-09 2004-11-09 Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential Active DE602004017477D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04292645A EP1655021B1 (de) 2004-11-09 2004-11-09 Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential

Publications (1)

Publication Number Publication Date
DE602004017477D1 true DE602004017477D1 (de) 2008-12-11

Family

ID=34931510

Family Applications (5)

Application Number Title Priority Date Filing Date
DE602004017477T Active DE602004017477D1 (de) 2004-11-09 2004-11-09 Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
DE602005012136T Active DE602005012136D1 (de) 2004-11-09 2005-10-10 Ophthalmische öl-in-wasser-emulsion mit stabilem positivem zeta-potential
DE602005010733T Active DE602005010733D1 (de) 2004-11-09 2005-10-10 Ophthalmische emulsion mit einem immunosuppressiven mittel
DE602005011480T Active DE602005011480D1 (de) 2004-11-09 2005-10-10 Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
DE602005026464T Active DE602005026464D1 (de) 2004-11-09 2005-10-10 Ophthalmische Emulsionen mit einem immunsuppressiven Mittel

Family Applications After (4)

Application Number Title Priority Date Filing Date
DE602005012136T Active DE602005012136D1 (de) 2004-11-09 2005-10-10 Ophthalmische öl-in-wasser-emulsion mit stabilem positivem zeta-potential
DE602005010733T Active DE602005010733D1 (de) 2004-11-09 2005-10-10 Ophthalmische emulsion mit einem immunosuppressiven mittel
DE602005011480T Active DE602005011480D1 (de) 2004-11-09 2005-10-10 Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
DE602005026464T Active DE602005026464D1 (de) 2004-11-09 2005-10-10 Ophthalmische Emulsionen mit einem immunsuppressiven Mittel

Country Status (14)

Country Link
US (5) US8298568B2 (de)
EP (1) EP1655021B1 (de)
JP (3) JP5587936B2 (de)
CN (3) CN101056615B (de)
AT (5) ATE412400T1 (de)
DE (5) DE602004017477D1 (de)
DK (1) DK1809237T3 (de)
ES (4) ES2314354T3 (de)
HK (2) HK1107938A1 (de)
IL (3) IL181446A (de)
MX (2) MX2007003045A (de)
NZ (1) NZ554929A (de)
PT (2) PT1809237E (de)
ZA (1) ZA200703751B (de)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US8232320B2 (en) 1999-04-28 2012-07-31 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
EP1871349A1 (de) * 2005-04-11 2008-01-02 Nanobio Corporation Quartäre ammoniumhalogenide zur behandlung von infektionskrankheiten
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
CA2618974C (en) * 2005-08-09 2014-01-28 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US7797337B2 (en) * 2005-09-29 2010-09-14 Scenera Technologies, Llc Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource
CA2645080A1 (en) * 2006-03-07 2007-09-13 Novavax,Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
CA2681668C (en) 2006-03-23 2014-04-01 Michael S. Singer Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
US20080026013A1 (en) * 2006-07-28 2008-01-31 Laura Rabinovich-Guilatt Compositions containing quaternary ammonium compounds
US9132071B2 (en) * 2006-07-28 2015-09-15 Santen Sas Compositions containing quaternary ammonium compounds
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
AU2014201978B2 (en) * 2006-07-28 2016-03-10 Santen Sas Compositions containing quaternary ammonium compounds
EP1891939B1 (de) * 2006-07-28 2013-09-11 Novagali Pharma S.A. Zusamensetzungen die quaternäre Ammonium Verbindungen enthalten
EP1901101A1 (de) 2006-09-14 2008-03-19 Carl Zeiss SMT AG Optische Elementeinheit und Verfahren zum Stützen eines optischen Elements
EP1938801A1 (de) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
EP1985298A1 (de) 2007-04-24 2008-10-29 Azad Pharma AG Prostaglandinhaltige Öl-in-Wasser-Emulsionen für das Auge
EP2152304B1 (de) 2007-05-02 2018-08-22 The Regents of the University of Michigan Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür
US20090018057A1 (en) * 2007-07-09 2009-01-15 Gregory Lambert OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES
US8512687B2 (en) * 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
CA2702478C (en) * 2007-10-16 2014-12-09 Sun Pharma Advanced Research Company Limited Ophthalmic composition
US7834172B2 (en) * 2007-11-14 2010-11-16 Novagali Pharma Sa Composition comprising at least one nucleosidic moiety as a therapeutic agent, and CKC
WO2009063081A2 (en) * 2007-11-14 2009-05-22 Novagali Pharma Sa Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc.
EP2077105A1 (de) * 2008-01-02 2009-07-08 Novagali Pharma SA Ophthalmische mizellare Zusammensetzung mit erhöhter Stabilität
EP2077104A1 (de) * 2008-01-02 2009-07-08 Novagali Pharma SA Mizellare Zusammensetzungen mit ophtalmischen Anwendungen
EP2127638A1 (de) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
MX2011002383A (es) * 2008-09-04 2011-04-07 Santen Pharma Co Ltd Agente para promover el crecimiento del pelo que contiene un derivado de 15,15-difluoroprostaglandina f2a como ingrediente activo.
BRPI0918806B1 (pt) * 2008-09-05 2019-02-05 Ceva Sante Animale Sa Composição de vacina compreendendo quitosana e antígeno do vírus de doença de newcastle (nvd) adaptada à administração ocular em ave, uso de quitosana e de nvd paraaumentar resposta imune em ave, bem como kit de vacinação de aves
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
CA2750242C (en) 2009-02-12 2018-05-22 Incept, Llc Drug delivery through hydrogel plugs
EP2228057A1 (de) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Kationische Öl-in-Wasser-Emulsionen mit Prostaglandinen und Verwendungen dafür
EP2228058A1 (de) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20130011354A1 (en) * 2009-11-09 2013-01-10 Allergan, Inc. Compositions For Enhancing Hair Growth
EP2389939A1 (de) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
CN103124541B (zh) * 2010-07-15 2015-09-30 艾诺维亚股份有限公司 眼药物递送
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
WO2012099942A2 (en) 2011-01-19 2012-07-26 Terakine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome
EP3388066B1 (de) 2011-01-26 2020-11-04 Allergan, Inc. Androgenzusammensetzung zur behandlung eines augenleidens
EP2734261B1 (de) 2011-07-18 2018-02-21 Mor-Research Applications Ltd. Vorrichtung zur einstellung des augeninnendrucks
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
CN104039308B (zh) 2011-11-15 2018-06-05 阿勒根公司 环孢菌素a形式2的可热压性悬浮液
WO2013074625A1 (en) 2011-11-15 2013-05-23 Allergan, Inc. Suspensions of cyclosporin a form 2
EP3613413A1 (de) 2011-12-05 2020-02-26 Incept, LLC Medizinische organogelprozesse und -zusammensetzungen
US8426471B1 (en) * 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
JP5992031B2 (ja) * 2012-02-24 2016-09-14 ファインバイオメディカル有限会社 潤滑性調整液
EP2887923B1 (de) 2012-08-24 2023-04-05 Sun Pharmaceutical Industries Limited Ophthalmische formulierung eines polyoxyllipids oder einer polyoxylfettsäure und behandlung von augenleiden
JP6408469B2 (ja) * 2012-09-06 2018-10-17 ナンヤン テクノロジカル ユニヴァーシティー ヒアルロン酸をベースとする薬物送達システム
EP2922542A4 (de) 2012-11-21 2016-10-05 Topokine Therapeutics Inc Verfahren und zusammensetzungen zur lokalen körperfettvermehrung
DK2948134T3 (da) 2013-01-24 2020-06-02 Palvella Therapeutics Inc Sammensætninger til transdermal indgivelse af mtor-inhibitorer
EP2964194B1 (de) 2013-03-05 2022-08-17 University of Pittsburgh - Of the Commonwealth System of Higher Education Wärmesensibles hydrogel mit polymerteilchen zur nichtinvasiven okularen arzneimittelfreisetzung
TWI623313B (zh) * 2013-03-13 2018-05-11 Santen Pharmaceutical Co Ltd 瞼板腺功能障礙之治療劑
US20140275261A1 (en) * 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
RU2513597C1 (ru) * 2013-04-17 2014-04-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения воспалительных состояний переднего отрезка глаза
NO2753788T3 (de) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
EP3013790A1 (de) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Verfahren zur herstellung von nepafenac
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
EP3104840B8 (de) 2014-02-11 2019-07-10 Latitude Pharmaceuticals Inc. Parenterale zusammensetzungen von celecoxib
US10251837B2 (en) 2014-02-14 2019-04-09 Jingjun Huang Compositions for nanoemulsion delivery systems
US20170087096A1 (en) * 2014-06-13 2017-03-30 Sanofi Nanocapsular formulation of active pharmaceutical ingredients
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
BR112017012655B1 (pt) * 2014-12-19 2022-11-01 Kemin Industries, Inc Uso de moléculas bioativas
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
KR20170113568A (ko) * 2015-02-06 2017-10-12 알.피.쉐러 테크놀러지즈 엘엘씨 폴리머 안정화된 약학 제제용 수중 유 에멀전의 제조
CN106176600A (zh) * 2015-05-07 2016-12-07 上海现代药物制剂工程研究中心有限公司 一种前列地尔冻干微乳剂、原料组合物及其制备方法
WO2016182926A1 (en) * 2015-05-08 2016-11-17 Affinsci Inc. Preparation of nanoemulsions
PT3373976T (pt) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Formulações tópicas e suas utilizações
WO2017151657A1 (en) 2016-02-29 2017-09-08 Ocular Technologies Sarl Topical cyclosporine-containing formulations and uses thereof
JP6906899B2 (ja) * 2016-03-30 2021-07-21 小林製薬株式会社 乳化組成物
US11285284B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency
US11285283B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for generating and delivering droplets to the pulmonary system using a droplet delivery device
KR102122887B1 (ko) 2016-05-03 2020-06-16 뉴마 레스퍼러토리 인코포레이티드 유체들의 폐기관계로의 전달을 위한 액적 전달 디바이스 및 사용 방법
US11285274B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device
WO2017192782A1 (en) 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment
US11395853B2 (en) 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
JOP20170147B1 (ar) * 2016-07-07 2021-08-17 Salvat Lab Sa تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة
CN106782348A (zh) * 2017-01-04 2017-05-31 深圳市华星光电技术有限公司 一种led背光驱动电路及液晶显示器
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
EP3634552A4 (de) 2017-05-19 2021-03-03 Pneuma Respiratory, Inc. Vorrichtung zur ausgabe von trockenpulver und verfahren zur verwendung
WO2018220444A2 (en) * 2017-05-30 2018-12-06 Eximore Ltd. Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide
SG11201911895XA (en) 2017-06-10 2020-01-30 Eyenovia Inc Methods and devices for handling a fluid and delivering the fluid to the eye
CN118203735A (zh) 2017-10-04 2024-06-18 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
EP4344719A3 (de) 2017-10-17 2024-06-05 Pneuma Respiratory, Inc. Nasale arzneimittelabgabevorrichtung und verwendungsverfahren
US11253480B2 (en) 2017-10-30 2022-02-22 University of Pittsburgh—of the Commonwealth System of Higher Education Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor
JP2021502178A (ja) 2017-11-08 2021-01-28 ニューマ・リスパイラトリー・インコーポレイテッド 小容積アンプルを有して呼吸により電気的に作動するインライン液滴送達装置および使用方法
CA3092016A1 (en) * 2018-02-26 2020-08-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Drug delivery systems
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
CN109010268B (zh) * 2018-09-28 2020-07-10 湖北远大天天明制药有限公司 一种提高氯霉素稳定性的眼用组合物及其制备方法
MX2021006912A (es) 2018-12-11 2021-08-24 Disruption Labs Inc Composiciones para la administracion de agentes terapeuticos y metodos de uso y fabricacion de las mismas.
CN110237233B (zh) * 2019-07-30 2021-01-15 沈阳兴齐眼药股份有限公司 一种含有环孢素的眼用药物组合物、其制备方法及用途
EP4069220A4 (de) * 2019-12-04 2024-04-24 Restore Vision, LLC. Ophthalmische formulierungen zur behandlung von presbyopie
CN116437909A (zh) * 2020-06-10 2023-07-14 迪斯拉普申实验室公司 用于递送治疗剂的组合物及其使用方法和制备方法
US11793945B2 (en) 2021-06-22 2023-10-24 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
CN113577024B (zh) * 2021-08-20 2023-05-05 山西利普达医药科技有限公司 一种眼用组合物及其制备方法和应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
JPH0818989B2 (ja) * 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
JP2602964B2 (ja) 1989-10-16 1997-04-23 裕 水島 プロスタグランジン類縁体およびその脂肪乳剤
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
IL103907A0 (en) * 1992-11-27 1993-04-04 Pharmos Corp Ophthalmic compositions
DE69328368T2 (de) * 1992-08-28 2000-08-10 Pharmos Corp., New York Emulsionen im submikron-bereich als vehikel zur arzneistoffverabreichung am auge
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
JP3551977B2 (ja) * 1993-04-08 2004-08-11 ライオン株式会社 安定なビタミンａ類及びビタミンｅ類可溶化点眼剤
ATE168553T1 (de) * 1993-06-25 1998-08-15 Alcon Cusi S A Neue verwendung von polymeren membranen zum ausgeben von pharmazeutischen lösungen, die quarternäre, als konserviermittel dienende ammoniumverbindungen enthalten und entsprechender dosierbehälter
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
WO1995032726A1 (en) * 1994-06-01 1995-12-07 Yuhan Corporation Cyclosporin containing composition and process for the preparation thereof
ES2094688B1 (es) * 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5767153A (en) * 1995-06-07 1998-06-16 Insite Vision Incorporated Sustained release emulsions
JP3410364B2 (ja) * 1997-05-14 2003-05-26 千寿製薬株式会社 ジフルプレドナート含有組成物
DE69807281T2 (de) 1997-05-14 2003-04-17 Mitsubishi Chemical Corp., Tokio/Tokyo Difluprednat enthaltende Zusammensetzungen
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6225348B1 (en) * 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
WO2000038663A2 (en) * 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US20020136771A1 (en) * 1998-12-31 2002-09-26 Amitee Cosmetics, Inc. Stabilized ascorbic acid composition
FR2823441B1 (fr) * 2001-04-12 2004-09-10 Thea Lab Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
CA2443937A1 (en) * 2001-04-23 2002-10-31 Randall D. Glickman Prostanoids augment ocular drug penetration
AU2002367976B2 (en) * 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
US6872705B2 (en) * 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
JP2005513097A (ja) * 2001-11-01 2005-05-12 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム ドライアイ治療方法および組成物
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
KR100446960B1 (ko) 2001-12-04 2004-09-01 김종국 프로스타글란딘 ｅ1을 포함하는 온도감응성 에멀젼 외용제조성물
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US20050124699A1 (en) * 2002-07-02 2005-06-09 Wakamoto Pharmaceutical Co., Ltd. Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells
CN100591333C (zh) 2002-08-23 2010-02-24 参天制药株式会社 以拉坦前列素为有效成分的稳定的滴眼液
CA2498233C (en) 2002-09-09 2012-08-14 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US20040115234A1 (en) * 2002-09-24 2004-06-17 Gewirtz Joan T. Cosmetic composition
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP4361294B2 (ja) * 2003-02-25 2009-11-11 ロート製薬株式会社 ケトチフェン含有組成物
JP4694773B2 (ja) * 2003-06-06 2011-06-08 ロート製薬株式会社 粘膜適用液状組成物
US20050059583A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
JP5382972B2 (ja) * 2003-12-26 2014-01-08 ロート製薬株式会社 粘度低下が防止された組成物
US20050175651A1 (en) * 2004-01-09 2005-08-11 L'oreal Aqueous dispersion of nanocapsules with an oily core
EP1611879B1 (de) 2004-07-02 2009-08-12 Novagali Pharma SA Verwendung von Emulsionen zur intra- und periocularen Injection
JP4999304B2 (ja) * 2004-09-27 2012-08-15 ロート製薬株式会社 ヒアルロン酸又はその塩を含有する粘膜適用組成物
EP1929996B1 (de) * 2004-11-09 2011-02-16 Novagali Pharma S.A. Ophthalmische Emulsionen mit einem immunsuppressiven Mittel
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
US20090170944A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Ophthalmic micellar compositions with enhanced stability
US20090169629A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Micellar compositions with ophthalmic applications
ES2586283T3 (es) * 2008-05-28 2016-10-13 Novartis Ag Emulsiones autoconservadas
EP2228058A1 (de) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
EP2228057A1 (de) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Kationische Öl-in-Wasser-Emulsionen mit Prostaglandinen und Verwendungen dafür
EP2389939A1 (de) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen

Also Published As

Publication number Publication date
ES2319129T3 (es) 2009-05-04
ES2314354T3 (es) 2009-03-16
IL190497A (en) 2012-01-31
JP5773941B2 (ja) 2015-09-02
CN101056615B (zh) 2011-05-11
DE602005011480D1 (de) 2009-01-15
JP2014088450A (ja) 2014-05-15
MX2007005545A (es) 2007-07-05
JP2012162549A (ja) 2012-08-30
JP5894202B2 (ja) 2016-03-23
ZA200703751B (en) 2008-08-27
US8273362B2 (en) 2012-09-25
ATE412401T1 (de) 2008-11-15
US8298568B2 (en) 2012-10-30
ATE418964T1 (de) 2009-01-15
IL182897A (en) 2010-12-30
MX2007003045A (es) 2007-08-02
DE602005012136D1 (de) 2009-02-12
DE602005026464D1 (de) 2011-03-31
PT1809238E (pt) 2009-02-09
ES2320574T3 (es) 2009-05-25
ATE412400T1 (de) 2008-11-15
ATE415942T1 (de) 2008-12-15
CN101056615A (zh) 2007-10-17
IL181446A (en) 2010-06-16
HK1112411A1 (en) 2008-09-05
EP1655021A1 (de) 2006-05-10
PT1809237E (pt) 2009-04-09
DE602005010733D1 (de) 2008-12-11
IL181446A0 (en) 2007-07-04
US8372434B2 (en) 2013-02-12
CN101014317A (zh) 2007-08-08
JP2012149102A (ja) 2012-08-09
IL190497A0 (en) 2008-11-03
ES2317319T3 (es) 2009-04-16
US20080107738A1 (en) 2008-05-08
US20090028955A1 (en) 2009-01-29
US8298569B2 (en) 2012-10-30
HK1107938A1 (en) 2008-04-25
CN103356481A (zh) 2013-10-23
EP1655021B1 (de) 2008-10-29
US20070248645A1 (en) 2007-10-25
ATE498392T1 (de) 2011-03-15
JP5587936B2 (ja) 2014-09-10
IL182897A0 (en) 2007-08-19
NZ554929A (en) 2010-09-30
DK1809237T3 (da) 2009-05-04
US20060100288A1 (en) 2006-05-11
US20080268020A1 (en) 2008-10-30
CN103356481B (zh) 2017-11-28

Similar Documents

Publication Publication Date Title
ATE412400T1 (de) Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
EA200600877A1 (ru) Наночастицы для доставки лекарств
WO2008013785A3 (en) Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
WO2007137237A3 (en) Treatment of protein misfolding
BRPI0411306A (pt) composições farmacêuticas compreendendo compostos ativos de vitamina d
WO2006108405A3 (de) Nanopartikel-wirkstoff-konjugate
BRPI0607728A2 (pt) complexo de lipoproteìna carregado reconstituìdo, composição farmacêutica, e, uso de um complexo de lipoproteìna carregado
WO2008070538A3 (en) Micellar nanoparticles comprising botulinum toxin
BRPI0906866A2 (pt) métodos e composições para administração oral de agentes terapêutico de proteína e peptídeo
TW200613004A (en) External preparation of solid/oil type
EP2481409A3 (de) Nanopartikel mit Rapamycin und Albumin als Antikrebsmittel
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
DK1429731T3 (da) Nanopartikelformuleringer indeholdende insulin
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
WO2006050837A3 (en) Ophthalmic emulsions containing an immunosuppressive agent
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
BRPI0607549A2 (pt) sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
EP2301531A3 (de) Kombinationen und modi zur verabreichung therapeutischer mittel und kombinationstherapie
WO2008085556A3 (en) Surfactant-free nanoparticles for drug delivery
ATE513562T1 (de) Nicht-spezifische immunstimulierende mittel
ATE507818T1 (de) Orale verabreichung eines calcitonins
WO2008048205A3 (en) Method for delivering hydrophobic drugs via nanocrystal formulations
ATE508740T1 (de) Mittel zur verringerung von müdigkeit
DE60310605D1 (de) Nanoteilchen zur verabreichung von wirkstoffen, verfahren zur herstellung dieser teilchen und diese enthaltende zusammensetzung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition